GenSight Biologics S.A. (GSGTF)
USD 0.24
(-92.26%)
USD 0.24
(-92.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.13 Million EUR | -66.92% |
| 2022 | 27.6 Million USD | -56.86% |
| 2021 | 64 Million USD | 11.97% |
| 2020 | 57.16 Million USD | 58.1% |
| 2019 | 36.15 Million USD | -13.89% |
| 2018 | 41.99 Million EUR | -43.46% |
| 2017 | 74.26 Million EUR | 19.18% |
| 2016 | 62.31 Million EUR | 57.98% |
| 2015 | 39.44 Million EUR | 166.22% |
| 2014 | 14.81 Million EUR | -21.49% |
| 2013 | 18.87 Million EUR | 31033.6% |
| 2012 | 60.61 Thousand EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | 16.73 Million EUR | -35.5% |
| 2023 Q3 | 9.13 Million EUR | -49.76% |
| 2023 FY | 9.13 Million EUR | -66.92% |
| 2023 Q4 | 9.13 Million EUR | 0.0% |
| 2023 Q2 | 18.17 Million USD | 8.63% |
| 2022 Q3 | 25.94 Million EUR | -38.77% |
| 2022 FY | 27.6 Million USD | -56.86% |
| 2022 Q1 | 40.52 Million EUR | -28.46% |
| 2022 Q2 | 42.36 Million EUR | 4.55% |
| 2022 Q4 | 25.94 Million EUR | 0.0% |
| 2021 Q3 | 56.64 Million EUR | -15.91% |
| 2021 Q4 | 56.64 Million EUR | 0.0% |
| 2021 Q2 | 67.36 Million EUR | 0.0% |
| 2021 FY | 64 Million USD | 11.97% |
| 2021 Q1 | 67.36 Million EUR | 42.23% |
| 2020 FY | 57.16 Million USD | 58.1% |
| 2020 Q4 | 47.36 Million EUR | 0.0% |
| 2020 Q3 | 47.36 Million EUR | 74.43% |
| 2020 Q2 | 27.15 Million EUR | 0.0% |
| 2020 Q1 | 27.15 Million EUR | -16.41% |
| 2019 Q4 | 32.48 Million EUR | 0.0% |
| 2019 Q1 | 30.97 Million EUR | -16.25% |
| 2019 Q2 | 30.97 Million EUR | 0.0% |
| 2019 Q3 | 32.48 Million EUR | 4.88% |
| 2019 FY | 36.15 Million USD | -13.89% |
| 2018 Q1 | 52.8 Million EUR | -15.13% |
| 2018 Q4 | 36.97 Million EUR | 0.0% |
| 2018 FY | 41.99 Million EUR | -43.46% |
| 2018 Q3 | 36.97 Million EUR | -29.96% |
| 2018 Q2 | 52.8 Million EUR | 0.0% |
| 2017 Q3 | 62.21 Million EUR | -16.01% |
| 2017 Q2 | 74.07 Million EUR | 0.0% |
| 2017 Q1 | 74.07 Million EUR | 25.05% |
| 2017 FY | 74.26 Million EUR | 19.18% |
| 2017 Q4 | 62.21 Million EUR | 0.0% |
| 2016 Q3 | 59.23 Million EUR | 0.0% |
| 2016 Q4 | 59.23 Million EUR | 0.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 62.31 Million EUR | 57.98% |
| 2015 FY | 39.44 Million EUR | 166.22% |
| 2015 Q3 | 36.31 Million EUR | 225.31% |
| 2015 Q4 | 36.31 Million EUR | 0.0% |
| 2015 Q2 | 11.16 Million EUR | 0.0% |
| 2015 Q1 | 11.16 Million EUR | -24.67% |
| 2014 Q4 | 14.81 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 FY | 14.81 Million EUR | -21.49% |
| 2014 Q3 | 14.81 Million EUR | 0.0% |
| 2013 FY | 18.87 Million EUR | 31033.6% |
| 2012 FY | 60.61 Thousand EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 52.7 Million USD | 82.672% |
| Skye Bioscience, Inc. | 11.94 Million USD | 23.52% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 92.987% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1553.988% |
| Qrons Inc. | 420.00 USD | -2174185.714% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1800.295% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -366.349% |
| BioStem Technologies, Inc. | 14.56 Million USD | 37.281% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2482.455% |
| CSL Limited | 38.02 Billion USD | 99.976% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 67.32% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 13.474% |
| Rebus Holdings, Inc. | 5000.00 USD | -182540.0% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -395224.675% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1084.983% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1228.318% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 76.492% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -26.486% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -11860.081% |
| SQZ Biotechnologies Company | 107.18 Million USD | 91.48% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -537.695% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -12519.36% |
| Mesoblast Limited | 667.9 Million USD | 98.633% |
| Marizyme, Inc. | 22.01 Million USD | 58.519% |
| Genus plc | 1.02 Billion USD | 99.112% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -572.285% |
| Pharming Group N.V. | 462.85 Million USD | 98.027% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -175.64% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1729.917% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1356.459% |
| ContraFect Corporation | 20.67 Million USD | 55.839% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2239.343% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2289.469% |
| IMV Inc. | 31.33 Million USD | 70.856% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -120.259% |
| MultiCell Technologies, Inc. | 126.22 USD | -7234886.531% |
| ONE Bio Corp. | 70.08 Million USD | 86.97% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -871.811% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 92.894% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -2015.289% |
| Q BioMed Inc. | 3.51 Million USD | -159.763% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 74.041% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -3395.141% |
| Biomind Labs Inc. | 73.81 Thousand USD | -12270.799% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 97.954% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -530.296% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 69.575% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -232.516% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -250.8% |
| GB Sciences, Inc. | 103.44 Thousand USD | -8728.136% |
| Alpha Cognition Inc. | 2.45 Million USD | -272.405% |
| HST Global, Inc. | 1526.00 USD | -598327.261% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -824.322% |
| Halberd Corporation | 10.13 Thousand USD | -90039.177% |
| Enzolytics Inc. | 361.7 Million USD | 97.475% |
| Agentix Corp. | 261.39 Thousand USD | -3393.603% |
| Resverlogix Corp. | 8.11 Million USD | -12.532% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -386.293% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.799% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 80.856% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1327.642% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -39986.037% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -2.043% |
| AVAX Technologies, Inc. | 7.37 Million USD | -23.788% |
| Zenith Capital Corp. | 7410.00 USD | -123138.866% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.73% |
| Ember Therapeutics, Inc. | 184.00 USD | -4962943.478% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2737.735% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -3393.978% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -884.093% |
| Kadimastem Ltd | 2.3 Million USD | -296.34% |
| Helix BioMedix, Inc. | 3.02 Million USD | -201.876% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -15894.675% |
| LadRx Corporation | 2.3 Million USD | -295.687% |
| Cell Source, Inc. | 195.17 Thousand USD | -4578.974% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2482.455% |
| NovAccess Global Inc. | 62.24 Thousand USD | -14570.351% |
| Affymax, Inc. | 7.44 Million USD | -22.692% |
| Itoco Inc. | 1.4 Million USD | -552.252% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -9446.609% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -8515.094% |
| Mobile Lads Corp. | 52.00 USD | -17561438.462% |
| CytoDyn Inc. | 11.13 Million USD | 17.996% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -6287.265% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -50973.826% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2269.05% |
| SYBLEU INC | 330.46 Thousand USD | -2663.354% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2130.461% |
| International Stem Cell Corporation | 5.39 Million USD | -69.425% |
| Bioxytran, Inc. | 137.63 Thousand USD | -6534.796% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 39.127% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 44.918% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -11459.494% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -956.117% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -21.485% |
| Neutra Corp. | 2851.00 USD | -320208.664% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 71.82% |
| PureTech Health plc | 693.97 Million USD | 98.684% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -13.145% |
| IXICO plc | 15.84 Million USD | 42.363% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -10.263% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 91.162% |
| CSL Limited | 38.02 Billion USD | 99.976% |
| Cellectis S.A. | 333.99 Million USD | 97.266% |